HolderBook

Burrage Capital Management LLC

Reported holdings as of Q2 2021, from 7 quarterly filings.

This filer last reported in Q2 2021; the most recent quarter on file across all filers is Q2 2026. Firms that restructure stop filing under one CIK and start under another, so a successor entity may hold these positions now under a similar name.

CIK
1796461
Reported value
$99.7M
Positions
22
Top 10 weight
70.7%
Filed
2021-08-16
Days after quarter end
47

Holdings

SecurityTickerValue SharesWeightWeight change Held Change
BIOCRYST PHARMACEUTICALS INCBCRX$13.7M864,91613.71%+6.58pp3qHELD
INTELLIA THERAPEUTICS INCNTLA$10.3M63,63410.33%+6.19pp3qHELD
EPIZYME INCEPZM$7.0M836,8026.97%+2.99pp7q+48.2%+$2.3M
ESSA PHARMA INCEPIX$6.8M237,4426.80%+1.21pp2qHELD
NEOGENOMICS INCNEO$6.7M147,9216.70%+0.92pp7qHELD
MEI PHARMA INCMEIPXXXX$6.6M2,331,3136.66%+0.18pp7qHELD
CRINETICS PHARMACEUTICALS INCRNX$5.6M294,6205.57%+2.20pp7q+8.2%+$419.0K
CYTOKINETICS INCCYTK$4.8M244,6734.85%+0.24pp6qHELD
AMICUS THERAPEUTICS INCFOLD$4.8M500,0004.83%-newNEW
HARMONY BIOSCIENCES HLDGS INHRMY$4.2M150,0004.25%+0.23pp2qHELD
INOZYME PHARMA INCINZY$4.1M242,5174.14%+1.42pp3q+43.1%+$1.2M
Y-MABS THERAPEUTICS INCYMAB$3.9M114,4543.88%+1.07pp7qHELD
MIRUM PHARMACEUTICALS INCMIRM$3.6M205,8663.57%+0.26pp3qHELD
ADC THERAPEUTICS SAADCT$3.0M124,8753.05%+0.58pp5qHELD
VERASTEM INCVSTMXXXX$2.9M705,5852.88%-newNEW
MERUS N VMRUS$2.8M130,6832.76%+0.55pp5qHELD
GERON CORPGERN$2.7M1,912,6732.70%+0.26pp2qHELD
AVROBIO INCAVRO$2.2M244,9202.18%-0.34pp3qHELD
REVOLUTION MEDICINES INCRVMD$1.6M50,0001.59%-newNEW
BLACK DIAMOND THERAPEUTICS IBDTX$1.3M110,4471.35%-0.82pp3qHELD
G1 THERAPEUTICS INCGTHX$1.0M47,7081.05%-1.25pp7q-59.5%-$1.5M
TURNING POINT THERAPEUTICS ITPTX$169.0K2,1640.17%-5.36pp6q-97.0%-$5.5M

By sector

Industry comes from the SIC code on each company's own SEC filings, which is self-reported and sometimes out of date. Derivative exposure is counted with the shares. Securities the SEC assigns no industry - funds, trusts, foreign issues - are shown as not classified rather than dropped.

Biotech & Pharma 51.0%Business Services 6.7%Not classified 42.3%
 
SectorValueShare
Biotech & Pharma$50.8M51.0%
Business Services$6.7M6.7%
Not classified$42.2M42.3%

Quarter by quarter

QuarterValuePositions NewAddedTrimmed ExitedTop 10 Days to file
Q2 2021$99.7M22332870.7%47
Q1 2021$123.4M277510557.1%47
Q4 2020$131.2M257215964.4%43
Q3 2020$126.7M273124265.0%44
Q2 2020$142.9M263410859.9%45
Q1 2020$101.6M319813757.9%44
Q4 2019$149.2M29000070.0%45

Rows marked UNVERIFIED ID, PLACEHOLDER ID, TICKER AS ID or NON-CUSIP ID carry an identifier that is not a valid CUSIP. They are shown because the filer reported that money, but treat the security named with caution - hover the chip for what is wrong with it, and see the methodology.

Held counts consecutive filings in which this manager reported the position, and can reach further back than the quarters listed above: the tabs begin at Q4 2018 because earlier coverage is too sparse to describe a market, but tenure is counted over every filing we hold, some reaching to 2007. A position sold and later rebought starts again from one.

Weight change is the shift in this position's share of the whole book, in percentage points. It is the more useful column: when money flows into or out of a broad fund, almost every holding is bought or sold at once, so added and trimmed largely track flows. A weight that rose while the book shrank is a decision. Both compare with the previous quarter this filer reported, not the previous calendar quarter.